熱門資訊> 正文
Syndax获得Revuforj治疗急性骨髓性白血病的额外适应症
2025-10-25 01:53
- 纳比特(NA) 0
- 盛大科技(SDA) 0
- Syndax製藥(SNDX) 0
- The US FDA has approved Syndax Pharmaceuticals' (NASDAQ:SNDX) Revuforj (revumenib) for relapsed or refractory acute myeloid leukemia in patients with a certain genetic mutation.
- The indication is for individuals with the disease who have the susceptible nucleophosmin 1 (NPM1) mutation and no other treatment options.
- Revuforj was first approved in 2024 for relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation.
- The menin inhibitor's new indication was granted based on results from a single-arm cohort of an open-label trial. The complete remission with partial hematological recovery rate was 23.1% and the median duration was 4.5 months.
More on Syndax Pharmaceuticals
- Making Money In Biotech Stocks
- Syndax Pharmaceuticals: Revumenib PDUFA Review mNPM1 AML And Move Towards MSS CRC
- Syndax Pharmaceuticals, Inc. (SNDX) Presents At Citi's Biopharma Back To School Conference Transcript
- Syndax resumed with Buy at Stifel on newly launched drugs
- Syndax jumps after Q2 beat; Citi issues upside catalyst watch
推薦文章
美股機會日報 | 美參議院通過終止特朗普全面關税決議！財報季多股績后大漲，亞馬遜盤前漲超12%
一周IPO | 滴普科技上市三日股價漲320%；明略科技、賽力斯下周上市；小馬智行、旺山旺水等5家招股中
新股申購 | 非洲嬰兒紙尿褲之王樂舒適今起招股，一手入場費5292.85港元
華盛早報 | 美參議院通過決議：終止特朗普「全球徵稅」！史上最大IPO？OpenAI預計2026年籌備上市；亞馬遜盤后狂飆14%
美股機會日報 | 特朗普：下調芬太尼關税！並於明年4月訪問中國；科技股績后波動加劇！谷歌盤前大漲超8%
鉅額AI投資何時見回報?三大科技巨頭考驗投資者耐心
AI業務勢頭火熱！Alphabet(GOOGL.US)再次上調資本支出指引，Q3雲積壓訂單升至1550億美元
星巴克(SBUX.US)復甦跡象初現！Q4營收超預期 同店銷售重回正增長
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
